What is Thalassemia Market Scope?
Thalassemia is a general term for a group of monogenic blood disorders, within which the body produces abnormal hemoglobin, leading to the destruction of red blood cells. This ultimately results in anemia. There are 2 main kinds of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being additional serious. Beta-thalassemia is a common chromosome recessive disorder worldwide and it's comparatively rare within the U.S. Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet want for a reliable treatment possibility still exists. Treatment of thalassemia is usually restricted to regular blood transfusions and iron chelation medical aid. Medication prescribed for hypochromic anemia largely cures symptoms and facet effects like anemia, pathology, and nutrition deficiency. However, gene medical aid is rising as a reliable treatment option for the disease.
The Thalassemia market study is being classified by Type (Alpha-Thalassemia and Beta Thalassemia), by Application (Hospital, Clinic, Research Institute and Laboratories) and major geographies with country level break-up.
The Thalassemia market would increase in the coming years due to the increasing prevalence of the disease. The rising knowledge and the research and development in this field are fueling the growth of the market. Many patients are dependent on transfusion, which is driving the growth of the market. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Thalassemia market throughout the predicted period.
Bluebird bio, Inc. (United States), Acceleron Pharma, Inc. (United States), Celgene Corporation (United States), GlaxoSmithKline plc (United Kingdom), Incyte Corporation (United States), Gamida Cell (Israel), Kiadis Pharma (Netherlands), La Jolla Pharmaceutical Company (United States) and IONIS Pharmaceuticals (United States) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Thalassemia market by Type, Application and Region.
On the basis of geography, the market of Thalassemia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Influencing Market Trend
- Adoption of The Transplants and Increased Awareness
- Growing Prevalence of Thalassemia
- Increasing Market of Bone Marrow Transplant
- Large Numbers of Transfusion Dependent Patients
- Escalating Healthcare Spending
- Rising Expenditure on Pharmaceuticals Research and Development
- High Cost of The Treatment
- Lack of Skilled Personnel
Key Target AudienceManufacturers of Thalassemia, Suppliers and distributors of Thalassemia, Governmental and Regulatory bodies, End-Users and Potential Investors
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Frequently Asked Questions (FAQ):
1. At what growth rate would the Thalassemia market expands?
The Global Thalassemia market is expected to see a growth of % during projected year 2020 to 2026.
2. Who are the prominent players of the Global Thalassemia market?
The prominent players of Global Thalassemia market are Bluebird bio, Inc. (United States), Acceleron Pharma, Inc. (United States), Celgene Corporation (United States), GlaxoSmithKline plc (United Kingdom), Incyte Corporation (United States), Gamida Cell (Israel), Kiadis Pharma (Netherlands), La Jolla Pharmaceutical Company (United States) and IONIS Pharmaceuticals (United States), to name a few.
3. What are the top priorities to focus for Thalassemia marketís growth?
In this highly competitive & fast evolving Thalassemia industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.